218 related articles for article (PubMed ID: 25305449)
1. Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
Liu L; Mason RP; Gimi B
Cancer Lett; 2015 Jan; 356(2 Pt B):462-9. PubMed ID: 25305449
[TBL] [Abstract][Full Text] [Related]
2. Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI.
Zhao D; Richer E; Antich PP; Mason RP
FASEB J; 2008 Jul; 22(7):2445-51. PubMed ID: 18263704
[TBL] [Abstract][Full Text] [Related]
3. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
4. The development of combretastatin A4 phosphate as a vascular targeting agent.
Chaplin DJ; Hill SA
Int J Radiat Oncol Biol Phys; 2002 Dec; 54(5):1491-6. PubMed ID: 12459376
[TBL] [Abstract][Full Text] [Related]
5. Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts.
Liu L; Beck H; Wang X; Hsieh HP; Mason RP; Liu X
PLoS One; 2012; 7(8):e43314. PubMed ID: 22937031
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
7. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.
Dziba JM; Marcinek R; Venkataraman G; Robinson JA; Ain KB
Thyroid; 2002 Dec; 12(12):1063-70. PubMed ID: 12593719
[TBL] [Abstract][Full Text] [Related]
8. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
10. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A4 phosphate.
West CM; Price P
Anticancer Drugs; 2004 Mar; 15(3):179-87. PubMed ID: 15014350
[TBL] [Abstract][Full Text] [Related]
12. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
13. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
14. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
15. Combretastatin A4 phosphate: background and current clinical status.
Young SL; Chaplin DJ
Expert Opin Investig Drugs; 2004 Sep; 13(9):1171-82. PubMed ID: 15330748
[TBL] [Abstract][Full Text] [Related]
16. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
Siemann DW; Chaplin DJ; Walicke PA
Expert Opin Investig Drugs; 2009 Feb; 18(2):189-97. PubMed ID: 19236265
[TBL] [Abstract][Full Text] [Related]
17. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
18. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
[TBL] [Abstract][Full Text] [Related]
20. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
